Heart Health Heart Disease hATTR Amyloidosis Guide hATTR Amyloidosis Guide Overview Symptoms Diagnosis Treatment Coping Signs and Symptoms of hATTR Amyloidosis By Colleen Doherty, MD Updated on February 24, 2024 Medically reviewed by Stella Bard, MD Print Table of Contents View All Table of Contents How It Affects the Body Neurological Symptoms Heart-Related Symptoms Digestive System Symptoms Eye-Related Symptoms Kidney Symptoms Head and CNS Symptoms Other Symptoms Next in hATTR Amyloidosis Guide Diagnosis and Genetic Testing for hATTR Amyloidosis Hereditary transthyretin (hATTR) amyloidosis is a rare disease that runs in families. It is caused by the buildup of toxic proteins called amyloid fibrils throughout the body. The amyloid fibrils damage tissues and organs, causing symptoms that worsen over time. The most common sites of amyloid buildup in hATTR amyloidosis are nerves and the heart. Other targeted areas include the stomach, intestines, eyes, kidneys, brain, and spinal cord. This article reviews the symptoms and signs of hATTR amyloidosis. Early recognition of this incurable disease is crucial to preventing or delaying disease progression and potentially life-threatening complications. supersizer / Getty Images How hATTR Amyloidosis Symptoms Affect the Body Hereditary ATTR amyloidosis occurs when a person inherits a faulty or mutated transthyretin (TTR) gene from either of their biological parents. The mutated TTR gene codes for unstable, misshapen proteins that clump together as amyloid fibrils in the body. The settling of amyloid fibrils within different organs prevents them from functioning normally, resulting in symptoms that develop in adulthood and worsen over time. Over 130 TTR gene mutations linked to hATTR amyloidosis have been identified. Symptoms, the extent of amyloid buildup, age of onset, and disease progression vary depending on the inherited genetic mutation. Unfortunately, these variations in clinical manifestations can delay the diagnosis of hATTR amyloidosis, sometimes as long as six years. Since current treatment options are most effective when taken in the early stages of the disease, a delayed diagnosis can negatively impact disease outcome (prognosis). What Is the Life Expectancy of hATTR Amyloidosis? Left untreated, the average life expectancy of hATTR amyloidosis is seven to 10 years after symptom onset. Neurological Symptoms Early symptoms of hATTR amyloidosis classically stem from damage to the peripheral nervous system (PNS). The PNS is a network of nerves that carry signals between the brain/spinal cord and the rest of the body. It consists of three types of nerves: Sensory nerves communicate signals to the brain about what a person touches, tastes, smells, and sees. Motor nerves transmit signals to the muscles about movement. Autonomic nerves control involuntary bodily functions like digestion, heartbeat, and sexual arousal. In hATTR amyloidosis, sensory symptoms include tingling and numbness (paresthesia), shooting or burning pain, and reduced sensitivity to heat. These symptoms are felt on both sides of the body and usually start in the toes and feet, progressing to the upper limbs over time. Motor symptoms, namely muscle weakness and stiffness, begin in the feet and lower legs and progress to walking difficulties. As the disease advances, a person can develop a reliance on assistive devices such as a wheelchair or they are not able to leave their beds. Common Early Manifestation: Bilateral Carpal Tunnel Syndrome Carpal tunnel syndrome is a peripheral nerve disease that affects the wrist's median nerve. Symptoms often involve both hands and include pain and tingling in the thumb and index, middle, and ring fingers. In some cases, finger and hand muscle weakness develops. Autonomic symptoms in hATTR amyloidosis include: Digestive tract problems like constipation, diarrhea, and early satiety (feeling full after only eating a small quantity of food) Orthostatic hypotension (light-headedness when standing up) Increased or decreased sweating Bladder dysfunction (e.g., retaining urine or incontinence) Erectile dysfunction Heart-Related Symptoms Amyloid deposition in the heart muscle in hATTR amyloidosis is called transthyretin amyloidosis cardiomyopathy. This condition causes the heart to stiffen and thicken, interfering with its ability to pump blood to the rest of the body. Transthyretin amyloidosis cardiomyopathy often leads to heart failure, which, when advanced, carries a poor prognosis and can be fatal. Symptoms and signs of heart failure in hATTR amyloidosis include: Difficulty breathing, especially when lying down or with minimal activity Swelling (edema) of the feet, ankles, lower legs, or belly Confusion or problems thinking Coughing or wheezing, mainly when lying down Unusual tiredness Dizziness and fainting Heart rhythm disorder (arrhythmia), especially heart block or atrial fibrillation Comprehensive Guide to Cardiac Amyloidosis Stomach and Digestive System Symptoms Stomach and bowel problems are relatively common in hATTR amyloidosis, affecting between 56% and 69% of individuals, depending on the inherited TTR gene mutation. Unintentional weight loss is the most common digestive system symptom in hATTR amyloidosis, followed by early satiety and colon (large intestine) problems like constipation, diarrhea, or alternating constipation and diarrhea. Other potential symptoms include: Bloating Abdominal pain Nausea and vomiting Fecal incontinence (loss of control over bowel movements) It's unclear, but experts suspect that amyloid-related damage to specific nerves, cells, and hormones responsible for gut motility and food absorption plays a role in leading to the above symptoms. Complications of gut involvement in hATTR amyloidosis include malnutrition, social isolation, and psychological distress for the person and their loved ones and caregivers. Diagnosis and Genetic Testing for hATTR Amyloidosis Eye-Related Symptoms Eye-related manifestations are frequent in hATTR amyloidosis, can impair vision, and tend to increase with disease duration. Eye manifestations and symptoms include: Vitreous opacities: Spots ("eye floaters") within the gel-like substance that fills the eyeball Glaucoma: Increased pressure within the eyeball Dilated (widening) the blood vessels in the eye's conjunctiva (clear membrane covering the white part of the eye and inside the eyelid) Irregularly shaped pupils (the black, center of the eye) Dry eyes Kidney Symptoms Most people have two kidneys, located below their ribcage on either side of the spine. The kidneys perform numerous functions, such as removing waste products from the body and maintaining electrolyte and fluid balances. Chronic kidney disease (CKD) involves the gradual loss of kidney function and affects approximately 30% of people with hATTR amyloidosis. Symptoms and signs of kidney damage and loss of function in hATTR amyloidosis include: Foamy urine from increased protein (proteinuria) Low protein levels in the blood Elevated blood creatinine level Swelling (edema) of the feet and ankles and around the eyes In addition, complications of CKD include weakened bones and anemia (low red blood cell count). With hATTR amyloidosis, CKD can eventually progress to end-stage renal disease (ESRD), where the kidneys basically stop working. At this point, dialysis is required to filter a person's blood. Head and Central Nervous System Symptoms The presence of central nervous system (CNS) symptoms—those related to the brain and spinal cord—is increased in people with longstanding hATTR amyloidosis. Interestingly, the accumulation of amyloid fibrils tends to appear in a distinct pattern. It usually starts in the leptomeninges (the two innermost layers of tissue covering the brain/spinal cord) and nearby blood vessels before progressing to deeper brain regions. The most common CNS manifestation of hATTR amyloidosis is transient focal neurological events (TFNEs), which are recurrent episodes of primarily sensory or motor symptoms lasting 10 to 30 minutes. A common TFNE symptom is paraesthesia in the hand or mouth, spreading to adjacent parts of the body. Other TFNE symptoms may be weakness of a body part, difficulty speaking, or visual disturbances. Additional potential CNS symptoms include: Hemorrhagic stroke (when an artery in the brain breaks open and bleeds) Ischemic stroke (when an artery that supplies oxygen-rich blood to the brain is blocked) Cognitive decline (thinking, memory, and concentration problems) Headache Seizures Other Associated Symptoms Other possible manifestations/symptoms of hATTR amyloidosis include: Nonspecific symptoms like fatigue, fever, and a general feeling of being unwell (malaise) An underactive thyroid gland (hypothyroidism) Hearing loss Skin changes, especially bruising around the eye (rare) Lumbar spinal stenosis (narrowing of the spinal canal in the lower back) Summary Hereditary ATTR (hATTR) amyloidosis is caused by a mutation (change in DNA sequence) in the transthyretin (TTR) gene, resulting in the accumulation of abnormal proteins (amyloid fibrils) in various organs. The peripheral nervous system and heart are the most commonly affected organs. Amyloid fibrils can also build up within the gut, eyes, kidneys, brain, and spinal cord, causing damage and organ dysfunction. Examples of peripheral nervous system symptoms include burning pain, numbness, tingling, muscle weakness, lightheadedness when standing up, and sexual dysfunction. Heart-related symptoms include trouble breathing, swelling of the ankles and lower legs, dizziness, and fainting. Additional symptoms or manifestations of hATTR amyloidosis include unexplained weight loss, kidney failure, decreased vision, dry eyes, and stroke-like episodes, among others. Hereditary ATTR amyloidosis is a rare, albeit disabling, life-threatening condition. That said, starting a disease-modifying therapy sooner than later can help slow or stop the buildup of amyloid protein. If you or a loved one is experiencing symptoms associated with hATTR amyloidosis, or if you have a family history of the disease, please reach out to a healthcare provider. If the diagnosis is suspected, ask for a referral to a medical center that specializes in managing amyloidosis. 22 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387-404. doi:10.1038/s41582-019-0210-4 Poli L, Labella B, Cotti Piccinelli S, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023;14:1242815. doi:10.3389/fneur.2023.1242815 Adams D, Théaudin M, Cauquil C, Algalarrondo V, Slama M. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435. doi:10.1007/s11910-013-0435-3 Tozza S, Severi D, Spina E, et al. The neuropathy in hereditary transthyretin amyloidosis: a narrative review. J Peripher Nerv Syst. 2021;26(2):155-159. doi:10.1111/jns.12451 Kuznecova I, Mierkyte G, Janciauskas D, et al. Impact of carpal tunnel syndrome surgery on early diagnosis and treatment of transthyretin cardiac amyloidosis. Medicina (Kaunas). 2023;59(2):335. doi:10.3390/medicina59020335 Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109-123. doi:10.2147/TCRM.S219979 Wang S, Peng W, Pang M, et al. Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in South China. Front Cardiovasc Med. 2022;9:900313. doi:10.3389/fcvm.2022.900313 American Heart Association. Transthyretin amyloid cardiomyopathy. Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61. doi:10.1186/1750-1172-9-61 Obici L, Suhr OB. Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clin Auton Res. 2019;29(Suppl 1):55-63. doi:10.1007/s10286-019-00628-6 Wixner J, Suhr OB, Anan I. Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years. Expert Rev Gastroenterol Hepatol. 2018;12(1):73-81. doi:10.1080/17474124.2018.1397511 Minnella AM, Rissotto R, Antoniazzi E, et al. Ocular involvement in hereditary amyloidosis. Genes (Basel). 2021;12(7):955. doi:10.3390/genes12070955 Ferraro PM, D'Ambrosio V, Di Paolantonio A, Guglielmino V, Calabresi P, Sabatelli M, Luigetti M. Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience. Brain Sci. 2021;11(8):980. doi:10.3390/brainsci11080980 Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294-1304. doi:10.1001/jama.2019.14745 Taipa R, Sousa L, Pinto M, et al. Neuropathology of central nervous system involvement in TTR amyloidosis. Acta Neuropathol. 2023;145(1):113-126. doi:10.1007/s00401-022-02501-9 Sanchez-Caro JM, de Lorenzo Martínez de Ubago I, de Celis Ruiz E, et al. Transient focal neurological events in cerebral amyloid angiopathy and the long-term risk of intracerebral hemorrhage and death: a systematic review and meta-analysis. JAMA Neurol. 2022;79(1):38-47. doi:10.1001/jamaneurol.2021.3989 Smith EE, Charidimou A, Ayata C, Werring DJ, Greenberg SM. Cerebral amyloid angiopathy–related transient focal neurologic episodes. Neurology. 2021;97(5):231-238. doi:10.1212/wnl.0000000000012234 Amyloidosis Research Consortium. Hereditary transthyretin amyloidosis. Huang G, Ueda M, Tasaki M, et al. Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation. Amyloid. 2017;24(1):24-29. doi:10.1080/13506129.2016.1276440 Bartier S, Bodez D, Kharoubi M, et al. Association between hearing loss and hereditary ATTR amyloidosis. Amyloid. 2019;26(4):234-242. doi:10.1080/13506129.2019.1663814 Jhawar N, Reynolds J, Nakhleh R, Lyle M. Hereditary transthyretin amyloidosis presenting with spontaneous periorbital purpura: a case report. Eur Heart J Case Rep. 2023;7(3):ytad108. doi:10.1093/ehjcr/ytad108 Çakar A, Atmaca MM, Kotan D, et al. Lumbar spinal stenosis: a rare presentation of hereditary transthyretin amyloidosis. Noro Psikiyatr Ars. 2020;59(1):77-79. doi:10.29399/npa.26124 By Colleen Doherty, MD Dr. Doherty is a board-certified internist and writer living with multiple sclerosis. She is based in Chicago. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit